Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
about
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes MellitusLack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion modelVariant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides.The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.Prospects and challenges for islet regeneration as a treatment for diabetes: a review of islet neogenesis associated protein.Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.Intron 1 sequences are required for pancreatic expression of the human proglucagon gene.The changes of pro-opiomelanocortin neurons in type 2 diabetes mellitus rats after ileal transposition: the role of POMC neurons.Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
P2860
Q28395801-98A1E86E-7D6D-4A5F-89F7-264BC8CE7AF3Q33486125-BEBDC3CA-8964-4170-89B3-D6D6EBF820C0Q36363950-6894AAD4-649F-4314-9588-3DD033029CFFQ36535937-3E00AE2D-401D-4C83-8C28-35B1609E062DQ36693199-E6B839A8-48F3-42D8-8B01-8C0F45F792B8Q36764031-E74BDD0C-57C8-4F5E-93F7-F1ECFDF5193CQ36928283-D116DDAC-B838-46DE-9BC7-2518AA832CB6Q37407901-4E8CF204-0A12-4F73-B2BD-05435EE311E6Q40237694-53C50D01-BC6A-4AA6-BEEC-0269AD5746A2Q40362284-8722959C-53AF-495C-B9EB-254A0E02FA06Q45914265-014454B5-CB09-437E-8A5A-5EAF793C1C8EQ48329014-9B4BB6E7-E51F-4DCA-A224-5C752872939DQ53186529-EFB334F6-08C0-49F9-9392-83BBB7CA543F
P2860
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
@ast
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
@en
type
label
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
@ast
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
@en
prefLabel
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
@ast
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
@en
P356
P1476
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
@en
P2093
P304
P356
10.1055/S-2004-826175
P577
2004-11-01T00:00:00Z